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Ubiquitin Proteasome System Impairment in 
Neurodegenerative Diseases and Aging
The proteasome in neurodegenerative diseases
A vast number of human, animal model, and cell model studies 
have indicated that the ubiquitin proteasome system (UPS) is 
impaired in various neurodegenerative diseases (NDs)—
Alzheimer, Parkinson, Huntington, prion, and others. It is not 
understood why the proteasome fails to rid the cell of such mis-
folded proteins before they oligomerize, eventually forming large 
aggregates. One explanation is, as proteasome activity decreases 
with age, the cell is more susceptible to protein accumulation and 
aggregation later in life, which is when NDs primarily occur, and 
a wide range of literature supports this hypothesis.1–5 In fact, 
impairment of the proteasome by mutagenesis or pharmacologic 
inhibition in mice, by itself, can cause pathologies and symptoms 
associated with ND.6 In addition, several well-known genetic 
causes of Alzheimer disease (AD), Parkinson disease (PD), and 
Amyotrophic Lateral Sclerosis (ALS) are due to disruptions of 
the UPS pathway. Currently, we do not understand the age-
related decline of UPS function but it does correlate with the late 
onset of many NDs. Proteasome function has been shown to be 
impaired in most NDs,7–12 and a recent genome-wide associa-
tion study has identified the UPS as a risk pathway for AD.13,14 
However, it has been difficult to elucidate the mechanism of 
inhibition that has been observed and though not all studies find 
UPS impairment the majority do.
In AD, the earliest pathologic hallmarks correlating with 
cognitive impairment is synaptic loss in the neocortex 
and hippocampus, which play important roles in learning and 
memory. Interestingly, there is weak correlation between insolu-
ble protein deposit pathology and disease severity, suggesting 
that other elements are responsible for neurotoxicity. The AD 
pathogenesis is characterized by the general accumulation of 
proteins, including misfolded metastable proteins such as amy-
loid β(Aβ) and tau. Even α-synuclein (α-syn), the primary mis-
folded protein found in PD, accumulates in subsets of AD. 
Huntingtin (htt) protein itself causes Huntington disease, when 
its poly-glutamine (polyQ) track gets expanded (ie, CAG repeat 
expansion), which slows its rapid degradation by the proteas-
ome and it accumulates into aggregates. These misfolded pro-
teins are normally degraded by the UPS (in their monomeric 
forms), which demonstrates that the UPS obviously does not 
function sufficiently to prevent their cellular accumulation in 
these diseases. It is now widely understood that small soluble 
oligomers play a key role in AD pathogenesis, which is based on 
their measurable toxicities and correlation with the severity of 
the disease.15–18 The most recent evidence indicates that specific 
small soluble Aβ oligomers are likely to be the initiating neuro-
toxic species in AD.19–21 In a similar fashion, small soluble oli-
gomers of tau are also found to be the earliest and most toxic 
misfolded forms of tau18,22–24 that contribute to disease severity. 
Although these 2 proteins spend most of their time isolated 
from each other, with Aβ outside the cell and tau inside (espe-
cially in axons), they can also be found together. In fact, Aβ is 
found in the cytosol with tau.25 Recent evidence showing that 
toxic oligomers can travel along neuronal pathways from cell to 
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cell, in a transmissible-like fashion, also points to a small soluble 
oligomers as pathogenic agents.26–28 Consistent with this model, 
evidence also suggests that the incorporation of toxic oligomers 
into large aggregates is actually protective for the cell,29–31 as 
some large aggregates are inert. Of course, when aggregates 
become large enough they can have other toxicities due to their 
sheer size (eg, by disrupting membranes or sequestering proteo-
stasis mechanisms such as protein chaperones or ubiquitin).32 
Likewise, this narrative is also shared by oligomers of α-syn33,34 
and htt,35,36 as evidence indicates that they too are likely the 
most neurotoxic species; however, this hypothesis has not been 
fully vetted especially regarding its generality. For instance, 
poly(GA)-containing aggregates can sequester and impair pro-
teasomes,37 whereas polyQ-containing aggregates do not.38 
Taken together, recent evidence supports a model whereby solu-
ble oligomers, perhaps even in cooperation with one another, are 
the primary pathogenic drivers of ND.
At the risk of oversimplifying, AD is, to the best of our cur-
rent knowledge, caused by the generation and accumulation of 
particular misfolded proteins that can form pathologic (or 
toxic) oligomers that impair synaptic function with associated 
mitochondrial dysfunction and ultimately neuronal cell death. 
Remarkably, the proteasome plays an essential role in main-
taining all 3 of these critical cellular processes that go awry in 
AD—misfolded protein degradation, synaptic function (LTP/
LTD),39,40 and mitochondrial function.41–43 Proteasome 
impairment has been pointed to as a major contributor to AD 
pathogenesis for years,23,44–48 as it has for many other NDs as 
well,7–12,49 but the evidence has only been correlative and no 
molecular mechanisms have been elucidated. Is it possible that 
a common mechanism for UPS impairment could be shared by 
all of these diseases?
Normal Proteasome Function
The principle degradative machinery of the UPS is the 26S 
proteasome which is a 2.5 MDa molecular machine that 
destroys the vast majority of proteins in the cell and its function 
is critical as it regulates essentially every cellular process.50 It is 
composed of an adenosine triphosphatase (ATPase) regulatory 
complex (19S) that binds to one or both ends of the 20S core 
proteasome51 where proteolysis occurs (Figure 1). The 20S is a 
cylindrical complex with a hollow center. The 19S and its 
ATPases (orange) are required for ubiquitin-dependent degra-
dation of folded substrates. As tightly folded proteins are too 
large to enter the 20S, the ATPases must use ATP to unfold 
proteins and inject them into the 20S for degradation. The 
outer rings of the 20S contain 7 α-subunits (α1-7; light blue) 
with a central pore. Proteins must translocate through this pore 
to enter the degradation chamber of 20S (β-subunits; dark 
blue). The translocation of proteins through this channel con-
stitutes a critical regulatory step in protein degradation as their 
passage is restricted by the N-termini of the α-subunits, which 
function as a substrate gate (Figure 1). The ATPase ring com-
plex opens this gate, allowing substrate entry during protein 
degradation, thus regulating proteolysis.52–55 The C-termini of 
these ATPases have a 3-residue motif called the HbYX motif 
that inserts into pockets on the outer α-ring of 20S that allows 
the 19S to bind to the 20S and induce gate-opening.
A Common Mechanism of Proteasome Impairment
Considering that protein degradation by the proteasome 
requires a complex multistep process, we reasoned that perhaps 
pathologic oligomers impair one of the steps in protein degra-
dation. Based on this, we investigated the hypothesis that there 
exists a universal mechanism of proteasomal impairment in 
NDs. We found that specific small soluble oligomers of 3 dis-
ease-related proteins (amyloid β, α-synuclein, and polyQ-
expanded Huntingtin) potently inhibit proteasome function,56 
which as we have discussed is not a particularly novel concept. 
The novel finding was that the amino acid sequence of the 
protein is unimportant for its ability to inhibit the proteasome. 
Instead, it is the misfolded tertiary structure of the protein that 
is critical for proteasome inhibition. We found that small solu-
ble oligomers of these 3 different proteins, when misfolded in a 
similar conformation, bind to and inhibit the proteasome with 
high affinity. These inhibitory oligomers are recognized by the 
A11 antibody, are known to be neurotoxic, and have been found 
in the brains of patients with different NDs. Our results thus 
introduce a general mechanism of proteasome impairment 
across the spectrum of NDs. We further demonstrated that 
these oligomers inhibit ubiquitin-dependent protein degrada-
tion by allosterically stabilizing the closed state of the 20S gate, 
thus inhibiting substrate entry.56 In short, A11+ oligomers 
regardless of their primary sequence can prevent the 19S from 
Figure 1. The 26S proteasome. Ubiquitinated proteins bound to the 19S 
are unfolded by the ATPases, which are injected through the opened gate 
and into the 20S for degradation. The 19S can bind to one or both ends of 
the 20S.
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inducing gate-opening in the 20S, which is required for sub-
strate injection and degradation. Because these inhibitory oli-
gomers have been found in many different NDs, we posit that 
this mechanism of proteasome impairment constitutes a gen-
eral and shared mechanism in these diseases. Moreover, as the 
inhibitory species of these ND-related proteins turns out to be 
a very specific oligomer with a specific conformation (only 
A11+ oligomers can inhibit), it is no surprise that some studies 
failed to find proteasome impairment because the A11+ oli-
gomers only form under the proper conditions and may not be 
present in all model systems. Studies investigating proteasome 
impairment in NDs typically use heterogeneous oligomer 
preparation without accounting for the different conforma-
tional states of the oligomers. Further efforts will be required to 
determine the extent to which this impairment mechanism 
elicits a physiological response in model organisms and in 
humans, but this initial discovery provides a tangible and direct 
mechanism of proteasome impairment that can be investigated 
in ND with currently available approaches. These findings thus 
bolster therapeutic efforts that are already ongoing, to find acti-
vators of proteasome function, and this study provides a mech-
anistic framework to do so as the general structure of the 26S 
proteasome is known (Figure 2).
Restoring and Enhancing Proteasome function in 
NDs
Because the mechanism of inhibition by oligomers is due to an 
allosteric effect on the 20S proteasome, it is possible that small 
molecules may reverse inhibition by oligomers. In fact, we have 
found that small peptides corresponding to the HbYX motif are 
able to reverse inhibition by these A11+ oligomers. However, 
the mechanism by which HbYX peptides induce gate-opening 
in the 26S core particle is not well-understood. Recent structural 
studies of the 26S proteasome indicate that understanding how 
the 19S ATPases induce gate-opening is not trivial, and future 
studies are required to clarify the mechanism. Nevertheless, the 
cryo-EM structure of the homologous archaeal 20S proteasome 
with the bound HbYX peptides has been generated.55 In this 
structure, HbYX binding to intersubunit pockets on top of the 
α-ring induces a rotation in the α-subunits, repositioning the 
base of the gating residues from a closed to an open gate confor-
mation. Understanding exactly where the A11+ oligomers bind 
to the 20S and elucidating the conformational changes that 
induce allosteric inhibition will be key to future efforts aimed at 
developing small molecules to reverse the inhibition. In the 
meantime, mutations to the 20S gating residues are also capable 
of inducing gate-opening and we showed that these mutations 
prevent allosteric inhibition by A11+ oligomers. Interestingly, a 
study by Choi et al showed that a similar gate-opening mutation 
enhances ubiquitin-dependent protein degradation in a human 
cell line. Future efforts are required to determine whether such 
mutations can alleviate proteasomal impairment in models of 
ND. A common mechanism of proteasome impairment in ND 
fits into the framework of what we have learned about protein 
degradation in ND in recent decades. If this mechanism is ubiq-
uitous in ND and plays a substantial pathologic role, then 
Figure 2. Pathologic oligomers from neurodegenerative diseases (NDs) inhibit the proteasome stabilizing its closed gate conformation. Misfolded 
proteins that oligomerize and are A11+ are potent allosteric inhibitors of the 20S and 26S proteasome, providing a general mechanism for proteasome 
impairment in protein misfolding disorders. Gate-opening by the HbYX mechanism directly opposes the allosteric inhibition by oligomers.
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therapeutics that counteract this mechanism would be very 
exciting, as they could provide a method for treating a funda-
mental component of ND. Regardless of this specific impair-
ment mechanism, finding ways to activate proteasome function 
would be expected to be beneficial to treat a root issue of these 
devastating proteinopathies.
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